ArticleThe Lancet regional health. Europe2025
Prevalence and prognosis of patients with breast cancer eligible for adjuvant abemaciclib or ribociclib: a nationwide population-based study.
Article in The Lancet regional health. Europe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00798070 (A Randomised Phase 3 Study Comparing Biweekly and Tailored Epirubicin + Cyclophosphamide Followed by Biweekly Tailored Docetaxel Versus Three Weekly Epirubicin + Cyclophosphamide + 5-fluorouracil Followed by Docetaxel in Lymph Node Positive or High Risk Lymph Node Negative Breast Cancer Patients), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomised Phase 3 Study Comparing Biweekly and Tailored Epirubicin + Cyclophosphamide Followed by Biweekly Tailored Docetaxel Versus Three Weekly Epirubicin + Cyclophosphamide + 5-fluorouracil Followed by Docetaxel in Lymph Node Positive or High Risk Lymph Node Negative Breast Cancer Patients
Who cites it
2 citing papers in PubMed.
- A nationwide population-based study on the incidence and prognosis of HER2-positive breast cancer eligible for adjuvant pertuzumab in the modern era of neoadjuvant therapy.Breast (Edinburgh, Scotland) · 2026Article
- Outcomes for patients with high-risk ER-positive, HER2-negative early-stage breast cancer: a Danish real-world study.Acta oncologica (Stockholm, Sweden) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nationwide studies on the prevalence, characteristics and long-term prognosis of patients with early breast cancer and a potential indication for adjuvant CDK4/6 inhibitors are lacking. Methods: We leveraged a prospectively collected nationwide cohort of all patients treated for breast cancer in Sweden in 2007-2023 and identified patients fulfilling the monarchE and/or the NATALEE eligibility criteria, to estimate the proportion of eligible patients for adjuvant CDK4/6 inhibitors and their outcomes. Overall survival (OS) was the primary endpoint of interest. In addition, we compared distant relapse-free survival and OS of a patient subset treated in the Stockholm-Gotland region in 2012-2020 to patients enrolled in the phase 3 PANTHER trial (NCT00798070) in 2007-2011, before and after alignment of key inclusion criteria. Findings: Of 52,602 patients with ER-positive, HER2-negative breast cancer, 9553 (18.2%) fulfilled both the monarchE and the NATALEE criteria, 9800 (18.6%) fulfilled the NATALEE criteria only and 745 patients (1.4%) fulfilled the monarchE criteria only. Median follow-up was 6.87 years. Ten-year OS rates were 65.7% (95% CI 65.3%-67.0%) for monarchE-eligible and 70.2% (95% CI 69.3%-71.1%) for NATALEE-eligible patients, and 84.0% (95% CI 83.4%-84.6%) for non-eligible, 75.5% (74.4$-76.7%) for NATALEE-only eligible and 64.3% (95% CI 62.9%-65.7%) for concordant eligible patients for both studies (p < 0.0001). Before alignment of inclusion criteria, patients treated within the PANTHER trial had improved outcomes compared to those treated in clinical routine. However, the differences in outcomes disappeared after alignment. Interpretation: These results inform on the prevalence and prognosis of candidates for adjuvant CDK4/6 inhibitors at a nationwide level. Funding: Cancerfonden, Bröstcancerförbundet, Radiumhemmets Forskningsfonder, Amgen, Roche, Sanofi-Aventis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.